Furthermore, the administration of the tumor-penetrating peptide iRGD and ROS-responsive nanoparticles concurrently enhanced the delivery efficiency of siFGL1 and siPD-L1, leading to a significant reduction in the protein levels of FGL1 and PD-L1 in tumor cells (113). Here, CD274 is linked to neoplasm.